Alain Mita, MD
Medical Oncology · San Antonio, TXNPI 1285602565
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Coherus Oncology, Inc. at 28.2% of the total. 2025 is the largest year on record at $4,832, 5.2 times the $930 reported in 2019.
Across 37 payments — averaging $229.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coherus Oncology, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Gilead$2K
- Life Technologies Corporation$496
- Pfizer$395
- Sanofi$350
- plus $1K from 13 others
Across 198 payments — averaging $12,429 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Co., Ltd.$578K
- Biontech SE$446K
- Pfizer$409K
- Merck$349K
- EMD Serono, Inc.$255K
- Janssen Research & Development, LLC$96K
- plus $328K from 10 others
What the payments were for
- Consulting fees$4,17049%
- Speaking & faculty fees$6808%
- Travel & lodging$1,83522%
- Food & beverage$1,66420%
- Education$1312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coherus Oncology, Inc. | 2 | $2,388 |
| E.r. Squibb & Sons, L.L.C. | 4 | $2,138 |
| Gilead | 5 | $1,595 |
| Life Technologies Corporation | 1 | $496 |
| Pfizer | 5 | $395 |
| Sanofi | 1 | $350 |
| Daiichi Sankyo Inc. | 3 | $273 |
| Theratechnologies Inc. | 1 | $120 |
| GSK | 1 | $120 |
| Merck | 4 | $117 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Seagen Inc. | 1 | $104 |
| Amgen | 2 | $65 |
| Tempus AI, Inc | 1 | $45 |
| Legend Biotech USA Inc. | 1 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,480 in reported general payments places this provider in the 55th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 14 | $357,489 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $138,997 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $779 |
| Ondansetron Hcl | 36 | $464 |
| Dexamethasone | 22 | $407 |
| Prochlorperazine Maleate | 38 | $296 |
| Olanzapine | 19 | $229 |
| Omeprazole | 16 | $99 |
| Prednisone | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.